PART 2 High-Dose for Atopic Dermatitis

"The current iteration of this study is ongoing at 4 sites, with physical centers in Encino, Towson, and New york among others. Opting for a site closest to you can reduce travel requirements during your potential involvement."

"To be considered for participation in this research study, individuals must be at least 18 years old but no older than 100."

"This clinical trial aims to enroll 210 individuals aged between 18 and 100 with atopic dermatitis. In addition, participants must fulfill the subsequent conditions: Both male and female volunteers aged 18 years or above, Must possess a vIGA score of 2 or 3 indicating mild to moderate AD during screening and baseline assessments, Ability to provide written consent for participation, Confirmed diagnosis of AD based on Hanifin and Rajka Criteria by a board-certified/eligible dermatologist at least half a year before screening, Affected area by AD should range from minimum of 5% to maximum of 30% total body"

"Indeed, information available on clinicaltrials.gov indicates that this current trial is actively seeking volunteers. The study was first listed on March 1, 2024, and most recently updated on April 24, 2024. A total of 210 participants are sought from four distinct locations."

"Based on our assessment at Power, we assign a safety rating of 2 to PART 2 High-Dose. This evaluation stems from the trial being classified as Phase 2; hence, there exists preliminary safety data without confirmed efficacy outcomes yet."